Overview compounds Audited

Oncology

Erbitux® (cetuximab, monoclonal anti-EGFR antibody)¹

Adjuvant colorectal cancer²

Phase III

Gastric cancer

Phase III

Cilengitide (integrin inhibitor)

Glioblastoma (brain tumor)

Phase III

Stimuvax® (cancer immunotherapy)³

Non-small cell lung cancer (NSCLC)

Phase III

Erbitux®

Breast cancer

Phase II

Cilengitide

Head and neck cancer (SCCHN)

Phase II

Non-small cell lung cancer (NSCLC)

Phase II

Monoclonal anti-integrin antibody (DI17E6)

Colorectal cancer

Phase II

TLR9 immunomodulator
(IMO-2055)⁴

Head and neck cancer (SCCHN)

Phase II

MEK inhibitor (AS703026/MSC1936369B)

Solid tumors and hematological diseases

Phase I

c-Met kinase inhibitors (EMD1214063, EMD1204831)⁵

Solid tumors

Phase I

Neurodegenerative
Diseases

Serum-free formulation of Rebif®

Relapsing-remitting forms of multiple sclerosis (MS)

USA: application submitted

Clinically isolated syndrome (CIS)

Phase III

Cladribine tablets

Relapsing-remitting forms of MS; Russia and Australia: approved, USA: application submitted⁶

Approved/ applications submitted

Clinically isolated syndrome (CIS)

Phase III

Safinamide⁷

Early-stage Parkinson’s disease

Phase III

Mid- to late-stage Parkinson’s disease

Phase III

Immune-tolerizing agent
(ATX-MS-1467)⁸

Relapsing-remitting forms of MS

Phase I

Extended-release formulation of interferon beta-1a⁹

Relapsing-remitting forms of MS

Phase I

Rheumatology

Atacicept (anti-BLyS/anti-APRIL fusion protein)¹⁰

Systemic lupus erythematosus (SLE)

Phase III

Fibroblast growth factor 18¹⁰

Cartilage injury

Phase II

Osteoarthritis

Phase I

Endocrinology

Long-acting growth hormone (ARX 201)¹¹

Growth hormone deficiency

Phase II